•
Dec 31, 2023

Prelude Therapeutics Q4 2023 Earnings Report

Total Revenue
$0
EPS
-$0.45
Previous year: -$0.6
-25.0%
Gross Profit
-$331K
Cash and Equivalents
$233M
Previous year: $30.6M
+661.1%
Free Cash Flow
-$24.7M
Previous year: -$23.3M
+5.9%
Total Assets
$278M
Previous year: $221M
+25.9%

Prelude Therapeutics

Prelude Therapeutics